EP3717019 - RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 19.04.2024 Database last updated on 03.09.2024 | |
Former | Request for examination was made Status updated on 04.09.2020 | ||
Former | The international publication has been made Status updated on 03.08.2019 | Most recent event Tooltip | 20.08.2024 | Change: Despatch of examination report + time limit | Applicant(s) | For all designated states Board of Regents of the University of Nebraska Verner Hall, 3835 Holdrege Street Lincoln, Nebraska 68583-0745 / US | [2020/41] | Inventor(s) | 01 /
GARRISON, Jered 1604 N. 154th Street Omaha, NE 68154 / US | 02 /
FAN, Wei 10821 Western Plaza, Apt. 13 Omaha, NE 68154 / US | 03 /
ZHANG, Wenting 726 N. 91st Plaza, No. 4308 Omaha, NE 68114 / US | [2020/41] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
Former [2020/41] | Potter Clarkson The Belgrave Centre Talbot Street Nottingham NG1 5GG / GB | Application number, filing date | 18902462.3 | 28.11.2018 | [2020/41] | WO2018US62781 | Priority number, date | US201762591465P | 28.11.2017 Original published format: US 201762591465 P | [2020/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2019147338 | Date: | 01.08.2019 | Language: | EN | [2019/31] | Type: | A2 Application without search report | No.: | EP3717019 | Date: | 07.10.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.08.2019 takes the place of the publication of the European patent application. | [2020/41] | Search report(s) | International search report - published on: | US | 07.11.2019 | (Supplementary) European search report - dispatched on: | EP | 20.08.2021 | Classification | IPC: | A61K51/08, A61K51/04, A61P35/00, C07K7/08 | [2021/38] | CPC: |
A61P35/00 (EP,US);
A61K51/0497 (EP,US);
A61K47/60 (US);
A61K47/65 (US);
A61K51/08 (EP);
A61K51/085 (EP,US);
C07K7/083 (EP,US);
A61K38/00 (EP,US);
A61K45/06 (US);
|
Former IPC [2020/41] | A61K47/64, A61K47/68 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/41] | Title | German: | RADIOPHARMAZEUTIKA UND VERFAHREN ZUR VERWENDUNG DAVON | [2020/41] | English: | RADIOPHARMACEUTICALS AND METHODS OF USE THEREOF | [2020/41] | French: | PRODUITS RADIOPHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION | [2020/41] | Entry into regional phase | 26.06.2020 | National basic fee paid | 26.06.2020 | Search fee paid | 26.06.2020 | Designation fee(s) paid | 26.06.2020 | Examination fee paid | Examination procedure | 26.06.2020 | Examination requested [2020/41] | 07.03.2022 | Amendment by applicant (claims and/or description) | 23.04.2024 | Despatch of a communication from the examining division (Time limit: M06) | Fees paid | Renewal fee | 13.11.2020 | Renewal fee patent year 03 | 10.11.2021 | Renewal fee patent year 04 | 14.11.2022 | Renewal fee patent year 05 | 27.10.2023 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2010256055 (CASTAIGNE JEAN-PAUL [CA], et al) [A] 1-7 * entire document *; | [A]US2014227175 (VASILJEVA OLGA [SI], et al) [A] 1-7* entire document *; | [XY]WO2016077505 (AMUNIX OPERATING INC [US]) [X] 1, 2, 5, 6 * entire document * [Y] 3, 4, 7; | [Y]US2017119913 (OSTERKAMP FRANK [DE], et al) [Y] 3, 4, 7 * entire document *; | [A]US2017319643 (REMALEY ALAN T [US], et al) [A] 1-7 * entire document *; | [PX] - FAN et al., "Increasing time on target: utilization of inhibitors of cysteine cathepsins to enhance the tumor retention of receptor-targeted agents", Chemical Communications, (20181004), vol. 54, no. 80, doi:10.1039/C8CC05982A, pages 11268 - 11271, XP055650672 [PX] 1-7 * . entire document * DOI: http://dx.doi.org/10.1039/C8CC05982A | by applicant | US2010256055 | US2014227175 | WO2016077505 | US2017119913 | US2017319643 | - FANI et al., Theranostics, (20120000), vol. 2, page 481 | - FISCHMAN et al., J. Nucl. Med., (19930000), vol. 34, page 2253 | - OKARVI, S.M., Cancer Treat. Rev., (20080000), vol. 34, page 13 | - OGBOMO et al., Nucl. Med. Biol., (20130000), vol. 40, no. 5, pages 606 - 617 | - FAN et al., Mol. Pharm., (20170000), vol. 14, no. 5, pages 1405 - 1417 | - FAN et al., Biomaterials, (20160000), vol. 103, pages 101 - 115 | - SHI et al., Biomaterials, (20140000), vol. 35, no. 22, pages 5760 - 5770 | - FAN et al., Chem. Commun. (Camb., (20180000), vol. 54, no. 80, pages 11268 - 11271 | - HERMANS et al., Pharmacol. Ther., (19980000), vol. 79, page 89 | - MYERS et al., ACS Chem. Biol., (20090000), vol. 4, page 503 | - JIA et al., Nucl. Med. Biol., (20150000), vol. 42, page 816 | - XING et al., Biochem. J., (19980000), vol. 332, page 499 | - VERDOES, J. Am. Chem. Soc., (20130000), vol. 135, page 14726 | - CHOWDHURY et al., J. Med. Chem., (20140000), vol. 57, page 6092 | - HASHIDA et al., J. Biochem., (19820000), vol. 91, page 1373 | - SIKLOS et al., ActaPharm. Sin. B, (20150000), vol. 5, page 506 | - REISER, J. Clin. Invest., (20100000), vol. 120, page 3421 | - PALERMO et al., Trends Pharmacol. Sci., (20080000), vol. 29, page 22 | - TURK et al., Biochim. Biophys. Acta, (20120000), vol. 1824, page 68 | - JOYCE et al., Cell Cycle, (20040000), vol. 3, page 1516 | - AGGARWAL et al., Proteomics Clin. Appl., (20140000), vol. 8, page 427 | - KOS et al., Future Med. Chem., (20140000), vol. 6, page 1355 | - SUDHAN et al., Pharmacol. Ther., (20150000), vol. 155, page 105 | - SALPETER, Oncogene, (20150000), vol. 34, page 6066 | - KRANTZ et al., Biochemistry, (19910000), vol. 30, page 4678 | - WAGNER et al., J. Med. Chem., (19940000), vol. 37, page 1833 | - POWERS et al., Chem. Rev., (20020000), vol. 102, page 4639 | - OTTO, Chem. Rev., (19970000), vol. 97, page 133 | - OFORI et al., ACS Chem. Biol., (19770000), vol. 10, page 1977 | - JIA et al., Bioconjugate Chem., (20160000), vol. 27, page 2658 | - WU et al., Front. Endocrinol., (20120000), vol. 3, page 184 | - REUBI, J.C., Endocrine Reviews, (20030000), vol. 24, no. 4, pages 389 - 427 | - LACOEUILLE et al., Medecine Nucleaire, (20180000), vol. 42, pages 32 - 44 | - BROMME et al., J. Curr. Pharm. Des., (20020000), vol. 8, page 1639 | - RUKAMP et al., In Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development, Taylor and Francis, (20020000), page 84 | - TOWATARI et al., FEBS Lett, (19910000), vol. 280, page 311 | - BLUM et al., Nat. Chem. Biol., (20070000), vol. 3, no. 668 | - VEGT et al., Eur. J. Nucl. Med. Mol. Imaging, (20110000), vol. 38, page 623 | - KATO et al., Nat. Chem. Biol., (20050000), vol. 1, page 33 | - DUMONT et al., J. Nucl. Med., (20130000), vol. 54, no. 5, pages 762 - 9 |